CTXR
Citius Pharmaceuticals, Inc.NASDAQHealthcare$0.85+0.67%ClosedMarket Cap: $9.5M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.23
P/S
2.44
EV/EBITDA
-0.10
DCF Value
$0.92
FCF Yield
-362.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
61.4%
Operating Margin
-950.9%
Net Margin
-909.9%
ROE
-52.5%
ROA
-25.6%
ROIC
-36.3%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 2026 | $3.9M | 65.5% | $-9.0M | $-8.2M | $-0.38 | — |
| Q4 2025 | $0.00 | -Infinity% | $-8.4M | $-8.0M | $-0.44 | — |
| FY 2025 | $0.00 | -Infinity% | $-38.5M | $-37.4M | $-3.38 | — |
| Q3 2025 | $0.00 | -Infinity% | $-8.8M | $-8.8M | $-0.80 | — |
| Q2 2025 | $0.00 | -Infinity% | $-11.3M | $-10.9M | $-1.27 | — |
| Q1 2025 | $0.00 | -Infinity% | $-10.0M | $-9.8M | $-1.30 | — |
| Q4 2024 | $155.9K | -34.4% | $-11.1M | $-10.8M | $-1.70 | — |
| FY 2024 | $0.00 | -Infinity% | $-42.0M | $-39.1M | $-5.97 | — |
| Q3 2024 | $0.00 | -Infinity% | $-10.6M | $-10.6M | $-1.57 | — |
| Q2 2024 | $0.00 | -Infinity% | $-11.0M | $-8.5M | $-1.34 | — |
| Q1 2024 | $0.00 | -Infinity% | $-9.3M | $-9.2M | $-1.45 | — |
| Q4 2023 | $0.00 | -Infinity% | $-10.1M | $-9.9M | $-0.06 | — |